|
[1] World Health Organization. Global tuberculosis report 2017[EB/OL]. Geneva:WHO, 2017.
|
|
[2] HORSBURGH CR Jr, BARRY CE 3rd, LANGE C. Treatment of tuberculosis[J]. N Engl J Med, 2015, 373 (22) :2149-2160.
|
|
[3] WU S, XIA Y, LV X, et al. Preventive use of hepatoprotectors yields limited efficacy on the liver toxicity of anti-tuberculosis agents in a large cohort of Chinese patients[J]. J Gastroenterol Hepatol, 2015, 30 (3) :540-545.
|
|
[4] TOSTMANN A, BOEREE MJ, AARNOUTSE RE, et al. Antituberculosis drug-induced hepatotoxicity:Concise up-to-date review[J]. J Gastroenterol Hepatol, 2008, 23 (2) :192-202.
|
|
[5] SAUKKONEN JJ, COHN DL, JASMER RM, et al. An official ATS statement:Hepatotoxicity of antituberculosis therapy[J].Am J Respir Crit Care Med, 2006, 174 (8) :935-952.
|
|
[6] METUSHI I, UETRECHT J, PHILLIPS E. Mechanism of isoniazid-induced hepatotoxicity:Then and now[J]. Br J Clin Pharmacol, 2016, 81 (6) :1030-1036.
|
|
[7] BASKARAN UL, SABINA EP. Clinical and experimental research in antituberculosis drug-induced hepatotoxicity:A review[J]. J Integr Med, 2017, 15 (1) :27-36.
|
|
[8] HACKETT ES, TWEDT DC, GUSTAFSON DL. Milk thistle and its derivative compounds:A review of opportunities for treatment of liver disease[J]. J Vet Intern Med, 2013, 27 (1) :10-16.
|
|
[9] KIDD PM. Bioavailability and activity of phytosome complexes from botanical polyphenols:The silymarin, curcumin, green tea, and grape seed extracts[J]. Altern Med Rev, 2009, 14 (3) :226-246.
|
|
[10] LEE JI, NARAYAN M, BARRETT JS. Analysis and comparison of active constituents in commercial standardized silymarin extracts by liquid chromatography-electrospray ionization mass spectrometry[J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2007, 845 (1) :95-103.
|
|
[11] SHERIF IO, AL-GAYYAR MM. Antioxidant, anti-inflammatory and hepatoprotective effects of silymarin on hepatic dysfunction induced by sodium nitrite[J]. Eur Cytokine Netw, 2013, 24 (3) :114-121.
|
|
[12] KARIMI G, VAHABZADEH M, LARI P, et al. Silymarin, a promising pharmacological agent for treatment of diseases[J]. Iran J Basic Med Sci, 2011, 14 (4) :308-317.
|
|
[13] AU AY, HASENWINKEL JM, FRONDOZA CG. Hepatoprotective effects of S-adenosylmethionine and silybin on canine hepatocytes in vitro[J]. J Anim Physiol Anim Nutr (Berl) , 2013, 97 (2) :331-341.
|
|
[14] SINGH M, SASI P, GUPTA VH, et al. Protective effect of curcumin, silymarin and N-acetylcysteine on antitubercular drug-induced hepatotoxicity assessed in an in vitro model[J]. Hum Exp Toxicol, 2012, 31 (8) :788-797.
|
|
[15] EMINZADE S, URAZ F, IZZETTIN FV. Silymarin protects liver against toxic effects of anti-tuberculosis drugs in experimental animals[J]. Nutr Metab (Lond) , 2008, 5 (1) :18.
|
|
[16] MANN A, PELZ T, RENNERT K, et al. Evaluation of HepaRG cells for the assessment of indirect drug-induced hepatotoxicity using INH as a model substance[J]. Hum Cell, 2017, 30 (4) :267-278.
|
|
[17] ABENAVOLI L, CAPASSO R, MILIC N, et al. Milk thistle in liver diseases:Past, present, future[J]. Phytother Res, 2010, 24 (10) :1423-1432.
|
|
[18] LIU Q, GARNER P, WANG Y, et al. Drugs and herbs given to prevent hepatotoxicity of tuberculosis therapy:Systematic review of ingredients and evaluation studies[J]. BMC Public Health, 2008, 8:365-372.
|
|
[19] LUANGCHOSIRI C, THAKKINSTIAN A, CHITPHUK S, et al. A double-blinded randomized controlled trial of silymarin for the prevention of antituberculosis drug-induced liver injury[J].BMC Complement Altern Med, 2015, 15 (1) :334.
|
|
[20] MARJANI M, BAGHAEI P, KAZEMPOUR DIZAJI M, et al.Evaluation of hepatoprotective effect of silymarin among under treatment tuberculosis patients:A randomized clinical trial[J]. Iran J Pharm Res, 2016, 15 (1) :247-252.
|
|
[21] ZHANG S, PAN H, PENG X, et al. Preventive use of a hepatoprotectant against anti-tuberculosis drug-induced liver injury:A randomized controlled trial[J]. J Gastroenterol Hepatol, 2016, 31 (2) :409-416.
|
|
[22] KNOBLOCH K, YOON U, VOGT PM, et al. Preferred reporting items for systematic reviews and Meta-analyses (PRISMA) statement and publication bias[J]. J Craniomaxillofac Surg, 2011, 39 (2) :91-92.
|
|
[23] HIGGINS J. Cochrane handbook for systematic reviews of interventions version 5. 1. 0[EB/OL]. (2011-03) . The Cochrane Collaboration, 2011. http://handbook. cochrane.org/.
|
|
[24] WAN X, WANG WQ, LIU JM, et al. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range[J]. BMC Med Res Methodol, 2014, 14 (1) :135.
|
|
[25] RAMANATHAN R, SIVANESAN K. Evaluation of ameliorative ability of Silibinin against zidovudine and isoniazid-induced hepatotoxicity and hyperlipidaemia in rats:Role of Silibinin in Phase I and II drug metabolism[J]. Chem Biol Interact, 2017, 273:142-153.
|
|
[26] GHOSH K, INDRA N, JAGADEESAN G. The ameliorating effect of centella asiatica ethanolic extract on albino rats treated with isoniazid[J]. J Basic Clin Physiol Pharmacol, 2017, 28 (1) :67-77.
|
|
[27] MARTIN SJ, SABINA EP. Amelioration of anti-tuberculosis drug induced oxidative stress in kidneys by spirulina fusiformis in a rat model[J]. Ren Fail, 2016, 38 (7) :1115-1121.
|
|
[28] EVAN PRINCE S, UDHAYA LB, SUNITHA PS, et al. Reparation of isoniazid and rifampicin combinatorial therapy-induced hepatotoxic effects by bacopa monnieri[J]. Pharmacology, 2016, 98 (1-2) :29-34.
|
|
[29] MARTIN SJ, BASKARAN UL, VEDI M, et al. Attenuation of anti-tuberculosis therapy induced hepatotoxicity by Spirulina fusiformis, a candidate food supplement[J]. Toxicol Mech Methods, 2014, 24 (8) :584-592.
|
|
[30] SRIVASTAVA RK, SHARMA S, VERMA S, et al. Influence of diabetes on liver injury induced by antitubercular drugs and on silymarin hepatoprotection in rats[J]. Methods Find Exp Clin Pharmacol, 2008, 30 (10) :731-737.
|
|
[31] WU JW, TSAI TH. Effect of silibinin on the pharmacokinetics of pyrazinamide and pyrazinoic acid in rats[J]. Drug Metab Dispos, 2007, 35 (9) :1603-1610.
|
|
[32] TASDUQ SA, PEERZADA K, KOUL S, et al. Biochemical manifestations of anti-tuberculosis drugs induced hepatotoxicity and the effect of silymarin[J]. Hepatol Res, 2005, 31 (3) :132-135.
|
|
[33] OOSTHUIZEN C, ARBACH M, MEYER D, et al. Diallyl polysulfides from allium sativum as immunomodulators, hepatoprotectors, and antimycobacterial agents[J]. J Med Food, 2017, 20 (7) :685-690.
|
|
[34] CRONJL, EDMONDSON N, EISENACH KD, et al. Iron and iron chelating agents modulate Mycobacterium tuberculosis growth and monocyte-macrophage viability and effector functions[J].FEMS Immunol Med Microbiol, 2005, 45 (2) :103-112.
|
|
[35] CHAN MK, CHAN PC, WONG KK, et al. Hepatitis B infection and renal transplantation:The absence of anti-delta antibodies and the possible beneficial effect of silymarin during acute episodes of hepatic dysfunction[J]. Nephrol Dial Transplant, 1989, 4 (4) :297-301.
|
|
[36] KATAOKA K, KONO Y, SUGIMOTO M, et al. Hepatocyteprotective and anti-oxidant effects of rifampicin on human chronic hepatitis C and murine acute hepatocyte disorder[J].Exp Ther Med, 2010, 1 (6) :1041-1047.
|
|
[37] CHENG S. To research the antiviral treatment of low grade chronic hepatitis B associated with tuberculosis patients (82 cases contrast analysis) [C]. Hepatology international conference:26th annual conference of the Asian Pacific Association for the Study of the Liver, China, 2017.
|
|
[38] BEDI S, GOEL A, CHAND N, et al. A prospective study for evaluating the effect of silymarin on hepatic functions in tubercular patients receiving dots[J]. Chest, 2009, 136:74S.
|
|
[39] CHENG S. The efficacy of silymarin on the prevention of hepatotoxicity from antituberculosis drugs[J]. Gastroenterology, 144 (5 Suppl 1) :s993.
|
|
[40] Clinicaltrials. gov. Effect of prophylactic use of silymarin on hepatotoxicity induced by anti-tuberculosis drugs (PESOHHERZ) [EB/OL].[2017-11-30]. https://clinicaltrials.gov/ct2/show/NCT01436929? term=silymarin&cond=tuberculosis&rank=1.
|
|
[41] LI J, LIN WF, PAN YY, et al. Protective effect of silibinin on liver injury induced by antituberculosis drugs[J]. Chin J Hepatol, 2010, 18 (5) :385-386.
|
|
[42] HU Z, YANG X, HO PC, et al. Herb-drug interactions:A literature review[J]. Drugs, 2005, 65 (9) :1239-1282.
|
|
[43] GU J, TANG SJ, TAN SY, et al. An open-label, randomized and multi-center clinical trial to evaluate the efficacy of Silibinin in preventing drug-induced liver injury[J]. Int J Clin Exp Med, 2015, 8 (3) :4320-4327.
|
|
[44] HEO E, KIM DK, OH SH, et al. Effect of prophylactic use of silymarin on anti-tuberculosis drugs induced hepatotoxicity[J]. Tuberc Respir Dis (Seoul) , 2017, 80 (3) :265-269.
|
|
[45] RAMAPPA V, AITHAL GP. Hepatotoxicity related to anti-tuberculosis drugs:Mechanisms and management[J]. J Clin Exp Hepatol, 2013, 3 (1) :37-49.
|
|
[46] LEE CM, LEE SS, LEE JM, et al. Early monitoring for detection of antituberculous drug-induced hepatotoxicity[J]. Korean J Intern Med, 2016, 31 (1) :65-72.
|
|
[47] METUSHI IG, ZHU X, CHEN X, et al. Mild isoniazid-induced liver injury in humans is associated with an increase in Th17cells and T cells producing IL-10[J]. Chem Res Toxicol, 2014, 27 (4) :683-689.
|
|
[48] METUSHIIG, CAI P, ZHU X, et al. A fresh look at the mechanism of isoniazid-induced hepatotoxicity[J]. Clin Pharmacol Ther, 2011, 89 (6) :911-914.
|
|
[49] SU M, CHEN H, WEI C, et al. Potential protection of vitamin C against liver-lesioned mice[J]. Int Immunopharmacol, 2014, 22 (2) :492-497.
|
|
[50] ABENAVOLI L, IZZO AA, MILIC'N, et al. Milk thistle (Silybum marianum) :A concise overview on its chemistry, pharmacological, and nutraceutical uses in liver diseases[J]. Phytother Res, 2018, 32 (11) :2202-2213.
|
|
[51] ABOUZID SF, AHMED HS, ABD EL, et al. Linear regression analysis of silychristin A, silybin A and silybin B contents in Silybum marianum[J]. Nat Prod Res, 2018.[Epub ahead of print]
|
DownLoad: